Use, Safety and Persistence of Biosimilars in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events of Targeted Therapies in Rheumatic Diseases (BIOBADASER)
16/11/2023
Bethencourt J, Otero-Valera L, MANERO J, Perez-Pampin E, Pérez Vera Y, MANRIQUE S, Bustabad Reyes M, Freire González M, Ruiz-Montesinos D, Mateo Soria L, Martín Domenech R, Moreno Ramos M, Alonso F, Castrejon I
ACR 2023
Bethencourt J, Otero-Valera L, MANERO J, Perez-Pampin E, Pérez Vera Y, MANRIQUE S, Bustabad Reyes M, Freire González M, Ruiz-Montesinos D, Mateo Soria L, Martín Domenech R, Moreno Ramos M, Alonso F, Castrejon I. Use, Safety and Persistence of Biosimilars in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events of Targeted Therapies in Rheumatic Diseases (BIOBADASER) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/use-safety-and-persistence-of-biosimilars-in-adult-patients-diagnosed-with-juvenile-idiopathic-arthritis-results-from-the-spanish-registry-of-adverse-events-of-targeted-therapies-in-rheumatic-diseas/
https://acrabstracts.org/abstract/use-safety-and-persistence-of-biosimilars-in-adult-patients-diagnosed-with-juvenile-idiopathic-arthritis-results-from-the-spanish-registry-of-adverse-events-of-targeted-therapies-in-rheumatic-diseas/